|Date:||21 December 2012|
|Subject:||MHRA asks for views on new corporate plan|
|Contact:||Press Office 020 3080 7651
Out-of-hours 07770 446 189
The Medicines and Healthcare products Regulatory Agency (MHRA) today launched a consultation asking for views from stakeholders on its draft 2013-18 corporate plan.
The draft plan gives the strategic direction for the MHRA. It sets out key challenges and opportunities it will face, objectives and activities to respond to these, and outcomes it hopes to achieve. The plan is structured around five themes:
- The role of regulation and the regulator
- Bringing innovation safely to market
- Strengthening surveillance
- Safe products and secure supply in globalised industries
- Achieving excellence - A well run, efficient and effective organisation.
The MHRA welcomes any views from stakeholders on whether it is proposing the right strategic direction for itself over the next five years. The consultation is open from 21 December 2012 to 1 February 2013, and you can respond via our electronic survey which is available on our website. www.mhra.gov.uk/corporateplan
Professor Sir Kent Woods, the MHRA’s Chief Executive, explains the new corporate plan here:
Notes to Editor1. The MHRA is the government agency responsible for ensuring that medicines and medical devices work, and are acceptably safe. No product is risk-free. Underpinning all our work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks. We keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem. We encourage everyone – the public and healthcare professionals as well as the industry – to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action.